The Innovative Medicines Initiative (IMI) is launching a new call for proposals covering cancer, neurodegenerative disease and medicines safety features.
The total budget of the call is €223m, around half of which comes from the EU’s Horizon 2020 programme, and the other half from European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and IMI’s associated partners.
The IMI is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need.
It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.
Several of the topics to be covered by the proposal will be: Diabetic Cardiomyopathy, Cancer, Medicines safety in pregnancy and during breastfeeding, Diagnostics for antimicrobial resistance (AMR) and Predicting medicines safety early in drug development.
Pierre Meulien, IMI executive director, said: “IMI calls for proposals represent an excellent opportunity for scientists from universities, small companies, and patient groups. Our Calls are about more than funding – they are a chance to join a global community of thousands of people from a range of sectors working together to accelerate and improve the entire drug development process, for the benefit of patients.”
You can find more details, here.